Adenovirus Vector Production and Purification

Current Gene Therapy

Volumn 10, Issue 6, 2010, Pages 437-455

  Silva, Ana Carina ^a   Peixoto, Cristina ^a   Lucas, Tanja ^b   Küppers, Claudia ^b   Cruz, Pedro E ^a   Alves, Paula M ^a   Kochanek, Stefan ^b  

^a INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Adenovirus; Adenovirus vector; Process development; Production; Production cell lines; Purification

Indexed keywords

ADENOVIRUS VECTOR;

ADENOVIRUS; ADENOVIRUS INFECTION; CELL CULTURE; CELL LINE; CELL STRAIN HEK293; CHROMATOGRAPHY; CULTURE MEDIUM; HUMAN; MONITORING; NONHUMAN; PROCESS DEVELOPMENT; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRUS PURIFICATION;

ADENOVIRIDAE; ANIMALS; CELL LINE; DNA REPLICATION; GENETIC VECTORS; HUMANS; TRANSGENES; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 78651330960     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652310793797694     Document Type: Review

References (177)

1. Lowenstein PR, Castro MG. Uncertainty in the translation of preclinicalexperiments to clinical trials. Why do most phase III clinicaltrials fail? Curr Gene Ther 2009; 9(5): 368-74.
2. Brunetti-Pierri N, Ng P. Progress towards liver and lung-directedgene therapy with helper-dependent adenoviral vectors. Curr Gene Ther 2009; 9(5): 329-40.
3. Jiang H, Gomez-Manzano C, Lang FF, et al. Oncolytic adenovirus:preclinical and clinical studies in patients with human malignantgliomas. Curr Gene Ther 2009; 9(5): 422-7.
4. Lusky M. Good manufacturing practice production of adenoviralvectors for clinical trials. Hum Gene Ther 2005; 16(3): 281-91.
5. McConnell MJ, Imperiale MJ. Biology of adenovirus and its use asa vector for gene therapy. Hum Gene Ther 2004; 15(11): 1022-33.
6. Imperiale MJ, Kochanek S. Adenovirus vectors: biology, design, and production. Curr Top Microbiol Immunol 2004; 273: 335-57.
7. Bangari DS, Mittal SK. Development of nonhuman adenoviruses asvaccine vectors. Vaccine 2006; 24(7): 849-62.
8. Gorziglia MI, Lapcevich C, Roy S, et al. Generation of an adenovirusvector lacking E1, e2a, E3, and all of E4 except open readingframe 3. J Virol 1999; 73(7): 6048-55.
9. Hodges BL, Serra D, Hu H, Begy CA, Chamberlain JS, Amalfitano A. Multiply deleted [E1, polymerase-, and pTP-] adenovirus vectorpersists despite deletion of the preterminal protein. J Gene Med 2000; 2(4): 250-9.
10. Parks RJ, Chen L, Anton M, Shankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal ofhelper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996; 93(24): 13565-70.
11. Umana P, Gerdes CA, Stone D, et al. Efficient FLPe recombinaseenables scalable production of helper-dependent adenoviral vectorswith negligible helper-virus contamination. Nat Biotechnol 2001; 19(6): 582-5.
12. Palmer DJ, Ng P. Methods for the production of helper-dependentadenoviral vectors. Methods Mol Biol 2008; 433: 33-53.
13. Sandig V, Youil R, Bett AJ, et al. Optimization of the helperdependentadenovirus system for production and potency in vivo. Proc Natl Acad Sci U S A 2000; 97(3): 1002-7.
14. Suzuki M, Cela R, Clarke C, Bertin TK, Mourino S, Lee B. Largescaleproduction of high-quality helper-dependent adenoviral vectorsusing adherent cells in cell factories. Hum Gene Ther 2010; 21(1): 120-6.
15. Kochanek S. High-capacity adenoviral vectors for gene transferand somatic gene therapy. Hum Gene Ther 1999; 10(15): 2451-9.
16. Palmer DJ, Ng P. Helper-dependent adenoviral vectors for genetherapy. Hum Gene Ther 2005; 16(1): 1-16.
17. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of ahuman cell line transformed by DNA from human adenovirus type5. J Gen Virol 1977; 36(1): 59-74.
18. Louis N, Evelegh C, Graham FL. Cloning and sequencing of thecellular-viral junctions from the human adenovirus type 5 transformed293 cell line. Virology 1997; 233(2): 423-9.
19. Shaw G, Morse S, Ararat M, Graham FL. Preferential transformationof human neuronal cells by human adenoviruses and the originof HEK 293 cells. Faseb J 2002; 16(8): 869-71.
20. Gallimore PH, Grand RJ, Byrd PJ. Transformation of human embryoretinoblasts with simian virus 40, adenovirus and ras oncogenes. Anticancer Res 1986; 6(3 Pt B): 499-508.
21. Byrd P, Brown KW, Gallimore PH. Malignant transformation ofhuman embryo retinoblasts by cloned adenovirus 12 DNA. Nature 1982; 298(5869): 69-71.
22. Fallaux FJ, Kranenburg O, Cramer SJ, et al. Characterization of911: a new helper cell line for the titration and propagation of earlyregion 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7(2): 215-22.
23. Lochmuller H, Jani A, Huard J, et al. Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (delta E1 + delta E3) duringmultiple passages in 293 cells. Hum Gene Ther 1994; 5(12): 1485-91.
24. Hehir KM, Armentano D, Cardoza LM, et al. Molecular characterizationof replication-competent variants of adenovirus vectorsand genome modifications to prevent their occurrence. J Virol 1996; 70(12): 8459-67.
25. Fallaux FJ, Bout A, van der Velde I, et al. New helper cells andmatched early region 1-deleted adenovirus vectors prevent generationof replication-competent adenoviruses. Hum Gene Ther 1998; 9(13): 1909-17.
26. Murakami P, Pungor E, Files J, et al. A single short stretch of homologybetween adenoviral vector and packaging cell line can giverise to cytopathic effect-inducing, helper-dependent E1-positiveparticles. Hum Gene Ther 2002; 13(8): 909-20.
27. Murakami P, Havenga M, Fawaz F, et al. Common structure ofrare replication-deficient E1-positive particles in adenoviral vectorbatches. J Virol 2004; 78(12): 6200-8.
28. Xie L, Metallo C, Warren J, et al. Large-scale propagation of areplication-defective adenovirus vector in stirred-tank bioreactorPER. C6 cell culture under sparging conditions. Biotechnol Bioeng 2003; 83(1): 45-52.
29. Lewis JA, Brown EL, Duncan PA. Approaches to the release of amaster cell bank of PER. C6 cells; a novel cell substrate for themanufacture of human vaccines. Dev Biol (Basel) 2006; 123: 165-76; discussion 183-97.
30. Ledwith BJ, Lanning CL, Gumprecht LA, et al. Tumorigenicityassessments of Per. C6 cells and of an Ad5-vectored HIV-1 vaccineproduced on this continuous cell line. Dev Biol (Basel) 2006; 123: 251-63; discussion 265-6.
31. Schiedner G, Hertel S, Kochanek S. Efficient transformation ofprimary human amniocytes by E1 functions of Ad5: generation ofnew cell lines for adenoviral vector production. Hum Gene Ther 2000; 11(15): 2105-16.
32. Schiedner G, Hertel S, Bialek C, Kewes H, Waschutza G, Volpers C. Efficient and reproducible generation of high-expressing, stablehuman cell lines without need for antibiotic selection. BMC Biotechnol 2008; 8: 13.
33. Imler JL, Chartier C, Dreyer D, et al. Novel complementation celllines derived from human lung carcinoma A549 cells support thegrowth of E1-deleted adenovirus vectors. Gene Ther 1996; 3(1): 75-84.
34. Gao GP, Engdahl RK, Wilson JM. A cell line for high-yield productionof E1-deleted adenovirus vectors without the emergence ofreplication-competent virus. Hum Gene Ther 2000; 11(1): 213-9.
35. Kim JS, Lee SH, Cho YS, Park K, Kim YH, Lee JH. Developmentof a packaging cell line for propagation of replication-deficientadenovirus vector. Exp Mol Med 2001; 33(3): 145-9.
36. Farson D, Tao L, Ko D, et al. Development of novel E1-complementary cells for adenoviral production free of replicationcompetentadenovirus. Mol Ther 2006; 14(2): 305-11.
37. Howe JA, Pelka P, Antelman D, et al. Matching complementingfunctions of transformed cells with stable expression of selected viralgenes for production of E1-deleted adenovirus vectors. Virology 2006; 345(1): 220-30.
38. Altaras NE, Aunins JG, Evans RK, Kemen A, Konz JO, Wolf JJ. Production and formulation of adenovirus vectors. Adv Biochem Eng Biotechnol 2005; 99: 193-260.
39. Segura MM, Alba R, Bosch A, Chillon M. Advances in helperdependentadenoviral vector research. Curr Gene Ther 2008; 8(4): 222-35.
40. Dormond E, Perrier M, Kamen A. From the first to the third generationadenoviral vector: what parameters are governing the productionyield? Biotechnol Adv 2009; 27(2): 133-44.
41. Iyer P, Ostrove JM, Vacante D. Comparison of manufacturingtechniques for adenovirus production. Cytotechnology 1999; 30(1-3): 169-72.
42. Okada T, Nomoto T, Yoshioka T, et al. Large-scale production ofrecombinant viruses by use of a large culture vessel with activegassing. Hum Gene Ther 2005; 16(10): 1212-8.
43. Wu SC, Huang GY, Liu JH. Production of retrovirus and adenovirusvectors for gene therapy: a comparative study using microcarrierand stationary cell culture. Biotechnol Prog 2002; 18(3): 617-22.
44. Graham FL. Growth of 293 cells in suspension culture. J Gen Virol 1987; 68(Pt 3): 937-40.
45. Garnier A, Cote J, Nadeau I, Kamen A, Massie B. Scale-up of theadenovirus expression system for the production of recombinantprotein in human 293S cells. Cytotechnology 1994; 15(1-3): 145-55.
46. Cote J, Bourget L, Garnier A, Kamen A. Study of adenovirus productionin serum-free 293SF suspension culture by GFP-expressionmonitoring. Biotechnol Prog 1997; 13(6): 709-14.
47. Schoofs G, Monica TJ, Ayala J, et al. A high-yielding serum-free, suspension cell culture process to manufacture recombinant adenoviralvectors for gene therapy. Cytotechnology 1998; 28(1-3): 81-9.
48. Xie L, Pilbrough W, Metallo C, et al. Serum-free suspension cultivationof PER. C6(R) cells and recombinant adenovirus productionunder different pH conditions. Biotechnol Bioeng 2002; 80(5): 569-79.
49. Park MT, Lee MS, Kim SH, Jo EC, Lee GM. Influence of culturepassages on growth kinetics and adenovirus vector production forgene therapy in monolayer and suspension cultures of HEK 293cells. Appl Microbiol Biotechnol 2004; 65(5): 553-8.
50. Berdichevsky M, Gentile MP, Hughes B, et al. Establishment ofhigher passage PER. C6 cells for adenovirus manufacture. Biotechnol Prog 2008; 24(1): 158-65.
51. Singh V. Disposable bioreactor for cell culture using wave-inducedagitation. Cytotechnology 1999; 30(1-3): 149-58.
52. Danthinne X, Imperiale MJ. Production of first generation adenovirusvectors: a review. Gene Ther 2000; 7(20): 1707-14.
53. Ballay A, Levrero M, Buendia MA, Tiollais P, Perricaudet M. Invitro and in vivo synthesis of the hepatitis B virus surface antigenand of the receptor for polymerized human serum albumin from recombinanthuman adenoviruses. EMBO J 1985; 4(13B): 3861-5.
54. Luo J, Deng ZL, Luo X, et al. A protocol for rapid generation ofrecombinant adenoviruses using the Ad Easy system. Nat Protocols 2007; 2(5): 1236-47.
55. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. Asimplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95(5): 2509-14.
56. Hokanson CA, Dora E, Donahue BA, Rivkin M, Finer M, Mendez MJ. Hybrid yeast-bacteria cloning system used to capture and modifyadenoviral and nonviral genomes. Hum Gene Ther 2003; 14(4): 329-39.
57. Blanche F, Cameron B, Barbot A, et al. An improved anionexchangeHPLC method for the detection and purification of adenoviralparticles. Gene Ther 2000; 7(12): 1055-62.
58. Subramanian S, Kim JJ, Harding F, Altaras GM, Aunins JG, Zhou W. Scaleable production of adenoviral vectors by transfection ofadherent PER. C6 cells. Biotechnol Prog 2007; 23(5): 1210-7.
59. Dormond E, Meneses-Acosta A, Jacob D, et al. An efficient andscalable process for helper-dependent adenoviral vector productionusing polyethylenimine-adenofection. Biotechnol Bioeng 2009; 102(3): 800-10.
60. Croyle MA, Roessler BJ, Davidson BL, et al. Factors that influencestability of recombinant adenoviral preparations for human genetherapy. Pharm Dev Technol 1998; 3(3): 373-83.
61. Obenauer-Kutner LJ, Ihnat PM, Yang TY, et al. The use of fieldemission scanning electron microscopy to assess recombinant adenovirusstability. Hum Gene Ther 2002; 13(14): 1687-96.
62. Croyle MA, Cheng X, Wilson JM. Development of formulationsthat enhance physical stability of viral vectors for gene therapy. Gene Ther 2001; 8(17): 1281-90.
63. Evans RK, Nawrocki DK, Isopi LA, et al. Development of stableliquid formulations for adenovirus-based vaccines. J Pharm Sci 2004; 93(10): 2458-75.
64. Cruz PE, Silva AC, Roldao A, Carmo M, Carrondo MJ, Alves PMScreening of novel excipients for improving the stability of retroviraland adenoviral vectors. Biotechnol Prog 2006; 22(2): 568-76.
65. Rexroad J, Wiethoff CM, Green AP, Kierstead TD, Scott MO, Middaugh CR. Structural stability of adenovirus type 5. J Pharm Sci 2003; 92(3): 665-78.
66. Rexroad J, Evans RK, Middaugh CR. Effect of pH and ionicstrength on the physical stability of adenovirus type 5. J Pharm Sci 2006; 95(2): 237-47.
67. Rexroad J, Martin TT, McNeilly D, Godwin S, Middaugh CR. Thermal stability of adenovirus type 2 as a function of pH. J Pharm Sci 2006; 95(7): 1469-79.
68. Yamada K, Morishita N, Katsuda T, Kubo S, Gotoh A, Yamaji H. Adenovirus vector production using low-multiplicity infection of293 cells. Cytotechnology 2009; 59(3): 153-60.
69. Nadeau I, Garnier A, Cote J, Massie B, Chavarie C, Kamen A. Improvement of recombinant protein production with the humanadenovirus/293S expression system using fed-batch strategies. Biotechnol Bioeng 1996; 51(6): 613-23.
70. Cote J, Garnier A, Massie B, Kamen A. Serum-free production ofrecombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnol Bioeng 1998; 59(5): 567-75.
71. Ferreira TB, Ferreira AL, Carrondo MJ, Alves PM. Two differentserum-free media and osmolality effect upon human 293 cellgrowth and adenovirus production. Biotechnol Lett 2005; 27(22): 1809-13.
72. Zhang S, Thwin C, Wu Z, Cho T, inventors; Method for the productionand purification of adenoviral vectors. US Patent 2001; 6194191 B1. 2001.
73. Liu LC, Shoupeng L, inventors; Method of producing adenoviralvector stocks. US Patent 6168941 B1. 2001.
74. Kamen A, Henry O. Development and optimization of an adenovirusproduction process. J Gene Med 2004; 6 Suppl 1: S184-92.
75. Henry O, Dormond E, Perrier M, Kamen A. Insights into adenoviralvector production kinetics in acoustic filter-based perfusion cultures. Biotechnol Bioeng 2004; 86(7): 765-74.
76. Cortin V, Thibault J, Jacob D, Garnier A. High-titer adenovirusvector production in 293S cell perfusion culture. Biotechnol Prog 2004; 20(3): 858-63.
77. Yuk IH, Olsen MM, Geyer S, Forestell SP. Perfusion cultures ofhuman tumor cells: a scalable production platform for oncolyticadenoviral vectors. Biotechnol Bioeng 2004; 86(6): 637-42.
78. Zhang C, Ferreira TB, Cruz PE, Alves PM, M. H, Carrondo MJT. The importance of 293 cell cycle phase on adenovirus vector production. Enzyme Microb Technol 2006; 39: 1328-1332.
79. Ferreira TB, Perdigao R, Silva AC, et al. 293 cell cycle synchronisationadenovirus vector production. Biotechnol Prog 2009; 25(1): 235-43.
80. Nadeau I, Gilbert PA, Jacob D, Perrier M, Kamen A. Low-proteinmedium affects the 293SF central metabolism during growth andinfection with adenovirus. Biotechnol Bioeng 2002; 77(1): 91-104.
81. Maranga L, Aunins JG, Zhou W. Characterization of changes inPER. C6 cellular metabolism during growth and propagation of areplication-deficient adenovirus vector. Biotechnol Bioeng 2005; 90(5): 645-55.
82. Nadeau I, Jacob D, Perrier M, Kamen A. 293SF metabolic fluxanalysis during cell growth and infection with an adenoviral vector. Biotechnol Prog 2000; 16(5): 872-84.
83. Henry O, Perrier M, Kamen A. Metabolic flux analysis of HEK-293 cells in perfusion cultures for the production of adenoviral vectors. Metab Eng 2005; 7(5-6): 467-76.
84. Jardon M, Garnier A. PH, pCO2, and temperature effect on Radenovirusproduction. Biotechnol Prog 2003; 19(1): 202-8.
85. Ferreira TB, Carrondo MJ, Alves PM. Effect of ammonia productionon intracellular pH: Consequent effect on adenovirus vectorproduction. J Biotechnol 2007; 129(3): 433-8.
86. Voisard D, Meuwly F, Ruffieux PA, Baer G, Kadouri A. Potentialof cell retention techniques for large-scale high-density perfusionculture of suspended mammalian cells. Biotechnol Bioeng 2003; 82(7): 751-65.
87. Mittereder N, March KL, Trapnell BC. Evaluation of the concentrationand bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70(11): 7498-509.
88. Park M, Lee G. Rapid titer assay of adenovirus containing greenfluorescent protein gene using flow cytometric analysis. Bioprocessand Biosystems Engineering 2000; 22: 403-406.
89. Kreppel F, Biermann V, Kochanek S, Schiedner G. A DNA-basedmethod to assay total and infectious particle contents and helper viruscontamination in high-capacity adenoviral vector preparations. Human Gene Therapy 2002; 13(10): 1151-6.
90. Ma L, Bluyssen HA, De Raeymaeker M, et al. Rapid determinationof adenoviral vector titers by quantitative real-time PCR. J Virol Methods 2001; 93(1-2): 181-8.
91. Wang F, Puddy AC, Mathis BC, et al. Using QPCR to assign infectiouspotencies to adenovirus based vaccines and vectors for genetherapy: toward a universal method for the facile quantitation of virusand vector potency. Vaccine 2005; 23(36): 4500-8.
92. Transfiguracion J, Bernier A, Arcand N, Chahal P, Kamen A. Validationof a high-performance liquid chromatographic assay for thequantification of adenovirus type 5 particles. J Chromatogr B Biomed Sci Appl 2001; 761(2): 187-94.
93. Shabram PW, Giroux DD, Goudreau AM, et al. Analytical anionexchangeHPLC of recombinant type-5 adenoviral particles. Human Gene Therapy 1997; 8(4): 453-65.
94. Hutchins B, Sajjadi N, Seaver S, et al. Working toward an adenoviralvector testing standard. Molecular Therapy: the Journal of theAmerican Society of Gene Therapy 2000; 2(6): 532-4.
95. Monica TJ, Montgomery T, Ayala JL, et al. Monitoring adenovirusinfections with on-line and off-line methods. Biotechnol Prog 2000; 16(5): 866-71.
96. Gilbert PA, Garnier A, Jacobb D, Kamen A. On-line measurementof green fluorescent protein (GFP) fluorescence for the monitoringof recombinant adenovirus production. Biotechnology Letters 2000; 22: 561-567.
97. Sandhu KS, Al-Rubeai M. Monitoring of the adenovirus productionprocess by flow cytometry. Biotechnol Prog 2008; 24(1): 250-61.
98. Renteria SS, Clemens CC, Croyle MA. Development of a nasaladenovirus-based vaccine: Effect of concentration and formulationon adenovirus stability and infectious titer during actuation fromtwo delivery devices. Vaccine; 28(9): 2137-48.
99. Klemperer HG, Pereira HG. Study of adenovirus antigens fractionatedby chromatography on DEAE-cellulose. Virology 1959; 9: 536-45.
100. Haruna I, Yaoi H, Kono R, Watanabe I. Separation of adenovirusby chromatography on DEAE-Cellulose. Virology 1961; 13: 264-7.
101. Philipson L. Separation on DEAE cellulose of components associatedwith adenovirus reproduction. Virology 1960; 10: 459-65.
102. Green M, Pina M. Biochemical studies on adenovirus multiplication. IV. Isolation, purification, and chemical analysis of adenovirus. Virology 1963; 20: 199-207.
103. Langer ES. Downstream Production Challenges in 2007. Bio Process Int 2007; 5: 22-28.
104. Lajmi AR, Kutner R, Reiser JA. A membrane chromatographyapplication: a rapid, high capacity gene therapy vector purificationtool. In: Process scale bioseparations for the biopharmaceutical industry.:Taylor & Francis, NW; 2007. p. 541.
105. Ferreira TB, Alves PM, Aunins JG, Carrondo MJ. Use of adenoviralvectors as veterinary vaccines. Gene Ther 2005; 12 Suppl 1:S73-83.
106. Schagen FH, Rademaker HJ, Rabelink MJ, et al. Ammonium sulphateprecipitation of recombinant adenovirus from culture medium:an easy method to increase the total virus yield. Gene Ther 2000; 7(18): 1570-4.
107. Konz JO, Lee AL, Lewis JA, Sagar SL. Development of a purificationprocess for adenovirus: controlling virus aggregation to improvethe clearance of host cell DNA. Biotechnol Prog 2005; 21(2): 466-72.
108. Konz JO, Pitts LR, Sagar SL. Scaleable purification of adenovirusvectors. Methods Mol Biol 2008; 434: 13-23.
109. Arcand N, Bernier A, Transfiguracion J, Kamen A. Adenovirustype 5 (Ad5)chromatographic purification process at 20L scale. Bioprocess J 2003; 2: 72-75.
110. Peixoto C, Ferreira TB, Carrondo MJ, Cruz PE, Alves PM. Purificationof adenoviral vectors using expanded bed chromatography. JVirol Methods 2006; 132(1-2): 121-6.
111. Roush DJ, Lu Y. Advances in primary recovery: centrifugation andmembrane technology. Biotechnol Prog 2008; 24(3): 488-95.
112. Goerke AR, To BC, Lee AL, Sagar SL, Konz JO. Development ofa novel adenovirus purification process utilizing selective precipitationof cellular DNA. Biotechnol Bioeng 2005; 91(1): 12-21.
113. Peixoto C, Ferreira TB, Sousa MF, Carrondo MJ, Alves PM. Towardspurification of adenoviral vectors based on membrane technology. Biotechnol Prog 2008; 24(6): 1290-6.
114. Langer ES, Price BJ. Disposables: Biopharmaceutical Disposablesas a Disruptive Future Technology. Biopharm International 2007; June.
115. Subramanian S, Altaras GM, Chen J, Hughes BS, Zhou W, Altaras NE. Pilot-scale adenovirus seed production through concurrent virusrelease and concentration by hollow fiber filtration. Biotechnol Prog 2005; 21(3): 851-9.
116. Lusky M. Good manufacturing practice production of adenoviralvectors for clinical trials. Hum Gene Ther 2005; 16(3): 281-91.
117. Albinana-Gimenez N, Clemente-Casares P, Calgua B, Huguet JM, Courtois S, Girones R. Comparison of methods for concentratinghuman adenoviruses, polyomavirus JC and noroviruses in sourcewaters and drinking water using quantitative PCR. J Virol Methods 2009; 158(1-2): 104-9.
118. Shabram P, Vellekamp G, Scandella C. Purification of adenovirus. In: Curiel DT, Douglas JT, editors. Adenoviral Vectors for Gene Theraphy.: Academic Press; 2002.
119. Konz JO, Livingood RC, Bett AJ, Goerke AR, Laska ME, Sagar SL. Serotype specificity of adenovirus purification using anionexchangechromatography. Hum Gene Ther 2005; 16(11): 1346-53.
120. Vellinga J, Van der Heijdt S, Hoeben RC. The adenovirus capsid:major progress in minor proteins. J Gen Virol 2005; 86(Pt 6): 1581-8.
121. Huyghe BG, Liu X, Sutjipto S, et al. Purification of a type 5 recombinantadenovirus encoding human p53 by column chromatography. Hum Gene Ther 1995; 6(11): 1403-16.
122. Klyushnichenko V, Bernier A, Kamen A, Harmsen E. Improvedhigh-performance liquid chromatographic method in the analysis ofadenovirus particles. J Chromatogr B Biomed Sci Appl 2001; 755(1-2): 27-36.
123. Green AP, Huang JJ, Scott MO, et al. A new scalable method forthe purification of recombinant adenovirus vectors. Hum Gene Ther 2002; 13(16): 1921-34.
124. Eglon MN, Duffy AM, O'Brien T, Strappe PM. Purification ofadenoviral vectors by combined anion exchange and gel filtrationchromatography. J Gene Med 2009; 11(11): 978-89.
125. Charcosset C. Membrane processes in biotechnology: an overview. Biotechnol Adv 2006; 24(5): 482-92.
126. Thoemmes JC, Kula M-R. Membrane chromatography-an integrativeconcept in the downstream processing of proteins. Biotechnol. Prog. 1995; 11: 357-367.
127. Ghosh R. Protein separation using membrane chromatography:opportunities and challenges. J Chromatogr A 2002; 952(1-2): 13-27.
128. Van Reis R, Zydney A. Bioprocess membrane technology. J Membrane Sci 2007; 297: 16-50.
129. Karger A, Bettin B, Granzow H, Mettenleiter TC. Simple and rapidpurification of alphaherpesviruses by chromatography on a cationexchange membrane. J Virol Methods 1998; 70(2): 219-24.
130. Specht R, Han B, Wickram asinghe SR, et al. Densonucleosis viruspurification by ion exchange membranes. Biotechnol Bioeng 2004; 88(4): 465-73.
131. Kalbfuss B, Wolf M, Geisler L, et al. Direct capture of influenza Avirus from cell culture supernatant with Sartobind anion-exchangemembrane adsorbers. J Membrane Sci 2007; 299: 251-260.
132. Duffy AM, O'Doherty AM, O'Brien T, Strappe PM. Purification ofadenovirus and adeno-associated virus: comparison of novel membrane-based technology to conventional techniques. Gene Ther 2005; 12 Suppl 1: S62-72.
133. Branovic K, Forcic D, Ivancic J, et al. Application of short monolithiccolumns for fast purification of plasmid DNA. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 801(2): 331-7.
134. Kramberger P, Peterka M, Boben J, Ravnikar M, Strancar A. Shortmonolithic columns--a breakthrough in purification and fast quantificationof tomato mosaic virus. J Chromatogr A 2007; 1144(1): 143-9.
135. Cheeks MC, Kamal N, Sorrell A, Darling D, Farzaneh F, Slater NK. Immobilized metal affinity chromatography of histidinetagged lentiviral vectors using monolithic adsorbents. J Chromatogr A 2009; 1216(13): 2705-11.
136. Whitfield RJ, Battom SE, Barut M, Gilham DE, Ball PD. Rapidhigh-performance liquid chromatographic analysis of adenovirustype 5 particles with a prototype anion-exchange analytical monolithcolumn. J Chromatogr A 2009; 1216(13): 2725-9.
137. Sutjipto S, Ravindran S, Cornell D, et al. Characterization of emptycapsids from a conditionally replicating adenovirus for gene therapy. Hum Gene Ther 2005; 16(1): 109-25.
138. Qu G, Bahr-Davidson J, Prado J, et al. Separation of adenoassociatedvirus type 2 empty particles from genome containingvectors by anion-exchange column chromatography. J Virol Methods 2007; 140(1-2): 183-92.
139. Urabe M, Xin K-Q, Obara Y, et al. Removal of empty capsids fromtype 1 adeno-associated virus vector stocks by anion-exchangechromatography potentiates transgene expression. Molecular Therapy 2006; 13: 823-28.
140. Vellekamp G, Porter F, Sutjipto S, et al. Empty capsids in columnpurifiedrecombinant adenovirus preparations. Hum Gene Ther 2001; 12: 1923-36.
141. Yang X, Agarwala S, Ravindran S, Vellekamp G. Determination ofparticle heterogeneity and stability of recombinant adenovirus byanalytical ultracentrifugation in Cs Cl gradients. J Pharm Sci 2008; 97(2): 746-63.
142. Lee DS, Kim BM, Seol DW. Improved purification of recombinantadenoviral vector by metal affinity membrane chromatography. Biochem Biophys Res Commun 2009; 378(3): 640-4.
143. Dormond E, Chahal P, Bernier A, Tran R, Perrier M, Kamen A. Anefficient process for the purification of helper-dependent adenoviralvector and removal of helper virus by iodixanol ultracentrifugation. J Virol Methods 2010; 165(1): 83-9.
144. Roitsch C, Achstetter T, Benchaibi M, et al. Characterization andquality control of recombinant adenovirus vectors for gene therapy. J Chromatogr B Biomed Sci Appl 2001; 752(2): 263-80.
145. Gijsbers L, Koel B, Weggeman M, Goudsmit J, Havenga M, Marzio G. Quantification of residual host cell DNA in adenoviral vectorsproduced on PER. C6 cells. Hum Gene Ther 2005; 16(3): 393-8.
146. Bauer SR, Pilaro AM, Weiss KD. Testing of Adenoviral Vector Gene Transfer Products: FDA Expectations. In: Curiel DT, Douglas JT, Editors. Adenoviral Vectors for Gene Theraphy: Academic Press; San Diego, USA 2002. p. 615-654.
147. Wright JF, Le T, Prado J, et al. Identification of factors that contributeto recombinant AAV2 particle aggregation and methods toprevent its occurrence during vector purification and formulation. Mol Ther 2005; 12(1): 171-8.
148. Mirza UA, Liu YH, Tang JT, et al. Extraction and characterizationof adenovirus proteins from sodium dodecylsulfate polyacrylamidegel electrophoresis by matrix-assisted laser desorption/ionizationmass spectrometry. J Am Soc Mass Spectrom 2000; 11(4): 356-61.
149. Darling A. Validation of biopharmaceutical purification processesfor virus clearance evaluation. Mol Biotechnol 2002; 21(1): 57-83.
150. FDA, CBER. Q5A: Viral safety evaluation of biotechnology productsderived from cell lines of human or animal origin. In: ICHSeretariat Guidelines; 1997.
151. FDA, CBER. Q6B: Specifications: Test procedures and acceptancecriteria for biotechnological/biological products. In: ICH Secretariat Guidelines; 1999.
152. Sidorenko Y, Reichl U. Structured model of influenza virus replicationin MDCK cells. Biotechnol Bioeng 2004; 88(1): 1-14.
153. Roldao A, Vieira HL, Charpilienne A, et al. Modeling rotaviruslikeparticles production in a baculovirus expression vector system:Infection kinetics, baculovirus DNA replication, mRNA synthesisand protein production. J Biotechnol 2007; 128(4): 875-94.
154. Carinhas N, Bernal V, Monteiro F, Carrondo MJ, Oliveira R, Alves PM. Improving baculovirus production at high cell density throughmanipulation of energy metabolism. Metab Eng 2010; 12(1): 39-52.
155. Gupta A, Rao G. A study of oxygen transfer in shake flasks using anon-invasive oxygen sensor. Biotechnol Bioeng 2003; 84(3): 351-8.
156. Teixeira AP, Oliveira R, Alves PM, Carrondo MJ. Advances in onlinemonitoring and control of mammalian cell cultures: Supportingthe PAT initiative. Biotechnol Adv 2009; 27(6): 726-32.
157. Teixeira AP, Portugal CA, Carinhas N, et al. In situ 2D fluorometryand chemometric monitoring of mammalian cell cultures. Biotechnol Bioeng 2009; 102(4): 1098-106.
158. Card CJ ST, Hunsaker B, Barnett B. Production of poliovirus, rubella virus, measles virus and recombinant adenovirus in proteinfreemedia: Springer, Dordrecht; 2005.
159. Ferreira TB, Ferreira AL, Carrondo MJ, Alves PM. Effect of refeedstrategies and non-ammoniagenic medium on adenovirus productionat high cell densities. J Biotechnol 2005; 119(3): 272-80.
160. Gardner TA, Ko SC, Yang L, Cadwell JJ, Chung LW, Kao C. Serum-free recombinant production of adenovirus using a hollowfiber capillary system. Biotechniques 2001; 30(2): 422-7.
161. Gilbert PA GA, Jacob D and Kamen A. On-line measurement ofgreen fluorescent protein (GFP) fluorescence for the monitoring ofrecombinant adenovirus production. Biotechnol Lett 2000; 22: 561-67.
162. Giroux DD, Goudreau AM, Ramachandra M, Shabram PW. Inventor Viral Production Process. US patent 5994134. 1999.
163. Lee YY, Yap MG, Hu WS, Wong KT. Low-glutamine fed-batchcultures of 293-HEK serum-free suspension cells for adenovirusproduction. Biotechnol Prog 2003; 19(2): 501-9.
164. Liu CH, Wu PS. Optimization of adenoviral production in humanembryonic kidney cells using response surface methodology. J Biosci Bioeng 2007; 103(5): 406-11.
165. Liu H, Liu XM, Li SC, et al. A high-yield and scaleable adenovirusvector production process based on high density perfusion cultureof HEK 293 cells as suspended aggregates. J Biosci Bioeng 2009; 107(5): 524-9.
166. Liu X, Wang Y, Niu H, Zhang X, Tan WS. The improvement ofadenovirus vector production by increased expression of coxsackieadenovirus receptor. Biotechnol Lett 2009; 31(7): 939-44.
167. Martinez V, Gerdtzen ZP, Andrews BA, Asenjo JA. Viral vectorsfor the treatment of alcoholism: use of metabolic flux analysis forcell cultivation and vector production. Metab Eng 2010; 12(2): 129-37.
168. Morishita N, Katsuda T, Kubo S, Gotoh A, Yamaji H. Immobilizationof 293 cells using porous support particles for adenovirus vectorproduction. Cytotechnology 2010. [Epub ahead of Print].
169. Racher AJ FA, Griffiths JB. Culture of 293 cells in different culturesystems: cell growth and recombinant adenovirus production. Biotechnol Tech 1995; 9(3): 169-74.
170. Shen CF, Voyer R, Tom R, Kamen A. Reassessing culture mediaand critical metabolites that affect adenovirus production. Biotechnol Prog 2010; 26(1): 200-7.
171. Tsao YS, Condon R, Schaefer E, Lio P, Liu Z. Development andimprovement of a serum-free suspension process for the productionof recombinant adenoviral vectors using HEK293 cells. Cytotechnology 2001; 37(3): 189-98.
172. Wong K, Guardia MJ, Lee S, Hu WS. Adenovirus vector productionin 293 fed-batch cultures.: Springer, Dordrecht; 1999.
173. Dormond E, Perrier M, Kamen A. Identification of critical infectionparameters to control helper-dependent adenoviral vector production. J Biotechnol 2009; 142(2): 142-50.
174. Longley R, Radzniak L, Santoro M, et al. Development of a serumfreesuspension process for the production of a conditionally replicatingadenovirus using A549 cells. Cytotechnology 2005; 49: 161-71.
175. Meneses-Acosta A, Dormond E, et al. Development of a suspensionserum-free helper-dependent adenovirus production systemand assessment of co-infection conditions. J Virol Methods 2008; 148(1-2): 106-14.
176. Palmer D, Ng P. Improved system for helper-dependent adenoviralvector production. Mol Ther 2003; 8(5): 846-52.
177. Tang JC, Vellekamp, G, Bondoc L. Inventor methods for purifyingviruses. US patent 6, 261,823 B1. 2001.